193 related articles for article (PubMed ID: 33318755)
1. Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.
Alanazi A; Yunusa I; Elenizi K; Alzarea AI
Lung Cancer Manag; 2020 Nov; 10(1):LMT43. PubMed ID: 33318755
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
3. An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.
Qi Y; Xia X; Shao L; Guo L; Dong Y; Tian J; Xu L; Niu R; Wei S
Front Oncol; 2022; 12():616546. PubMed ID: 35978809
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis.
Wu Z; Chen S; Du X; Wu Y; Xie X
J Clin Pharm Ther; 2021 Apr; 46(2):310-318. PubMed ID: 33031574
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis.
Zhang Z; Zeng K; Zhao S; Zhao Y; Hou X; Luo F; Lu F; Zhang Y; Zhou T; Ma Y; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Ther Adv Med Oncol; 2019; 11():1758835919891652. PubMed ID: 31908655
[TBL] [Abstract][Full Text] [Related]
7. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.
Holleman MS; van Tinteren H; Groen HJ; Al MJ; Uyl-de Groot CA
Onco Targets Ther; 2019; 12():1413-1421. PubMed ID: 30863108
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
9. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
10. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
13. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
Doval DC; Desai CJ; Sahoo TP
Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
[TBL] [Abstract][Full Text] [Related]
14. Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis.
Li XY; Lin JZ; Yu SH
Clin Ther; 2020 Feb; 42(2):338-350.e4. PubMed ID: 31937461
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.
Batson S; Mitchell SA; Windisch R; Damonte E; Munk VC; Reguart N
Onco Targets Ther; 2017; 10():2473-2482. PubMed ID: 28503070
[TBL] [Abstract][Full Text] [Related]
17. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis.
Zhao Y; Cheng B; Chen Z; Li J; Liang H; Chen Y; Zhu F; Li C; Xu K; Xiong S; Lu W; Chen Z; Zhong R; Zhao S; Xie Z; Liu J; Liang W; He J
Crit Rev Oncol Hematol; 2021 Apr; 160():103305. PubMed ID: 33757838
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and network meta-analysis of first-line therapy for advanced
Franek J; Cappelleri JC; Larkin-Kaiser KA; Wilner KD; Sandin R
Future Oncol; 2019 Aug; 15(24):2857-2871. PubMed ID: 31298572
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
